Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for Suicide

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02133001
Recruitment Status : Completed
First Posted : May 7, 2014
Last Update Posted : October 14, 2016
Sponsor:
Information provided by (Responsible Party):
Janssen Research & Development, LLC

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Completed
  Actual Primary Completion Date : February 2016
  Actual Study Completion Date : February 2016
  Certification/Extension First Submitted : October 13, 2016
Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 April 2, 2019